Pyxis Oncology, Inc. Annual Report - How They Did This Year

Are you curious about Pyxis Oncology (PYXS on Nasdaq)? This guide will help you understand their past year, how they're doing, and what it means for you as an investor. No fancy finance talk, just straightforward explanations.

What Pyxis Oncology Does (and What's New)

Pyxis Oncology develops new cancer treatments. They are a clinical-stage oncology company. This means they develop drugs and run trials. They don't sell products yet. Their main focus is head and neck squamous cell carcinoma (HNSCC), a type of cancer. The company started in 2018 and began operations in 2019. They built a team with deep experience in cancer research, drug development, and bringing new treatments to market.

Like many biotech companies, they work with others. This helps them develop and launch new drugs. They have key agreements. These include licenses with Pfizer, Biosion, Simcere, Toray, and Mabwell. They also partner with universities. These agreements help them access new technologies and therapies.

A big recent event was buying Apexigen, Inc. This acquisition happened on August 23, 2023. Such acquisitions can change a company's direction. They bring new research, technology, or talent. This can boost their drug pipeline, like the APXiMAB™ platform Pyxis now uses.

Their main drug candidate is micvotabart pelidotin (MICVO). It's still in early clinical development. It was previously called PYX-201. MICVO is an investigational antibody-drug conjugate (ADC). Think of it as a guided missile. It delivers a powerful drug directly to cancer cells.

MICVO is unique. It targets a protein called EDB+FN (extradomain-B of fibronectin). This protein is found near tumors, not directly on cancer cells. EDB+FN is rare in healthy adult tissues. But it's common in many solid tumors. This makes it a promising target.

MICVO works in a clever three-pronged way. It aims for better stability and anti-tumor activity than similar drugs:

1. Direct Cancer Cell Killing: It binds to EDB+FN near the tumor. A special "linker" breaks in the acidic tumor environment. This releases the drug (Aur0101). The drug then enters nearby cancer cells and kills them.
2. Additional Bystander Killing: Dying cancer cells release more drug. This drug then kills other nearby cancer cells. This is called the "bystander effect."
3. Immunogenic Cell Death (ICD): Dying cancer cells also trigger an immune response. This helps the body fight cancer.

EDB+FN is promising because it's in many solid tumors. This includes breast, lung, ovarian, pancreatic, and thyroid cancers, not just head and neck cancer. It appears even in early stages and grows with cancer. Importantly, it's rare in healthy adult tissues. Its broad presence in tumors and unique targeting are key. MICVO could deliver its drug directly to the tumor. It might even reshape the tumor's protective environment. All this happens while sparing healthy cells.

MICVO is studied in two ways. It's a standalone treatment (monotherapy) for recurrent and metastatic HNSCC. It's also combined with KEYTRUDA® (pembrolizumab) for HNSCC and other solid tumors.

Why Their Focus on Head and Neck Cancer Matters

Pyxis Oncology chose to prioritize MICVO for recurrent and metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC). This choice is strategic. There's a huge, unmet need for better treatments here.

• Common and Serious Cancer: Head and Neck Cancer is the seventh most common cancer globally. Experts predict one million new cases worldwide each year by 2030.
• Poor Survival Rates: R/M HNSCC means cancer has returned or spread. For these patients, the 5-year survival rate is very low, about 13%. Many U.S. patients (around 21,000 yearly) need second-line (2L) treatments or more. Options become limited, and survival drops sharply.
• Current Treatment Limits: Standard first-line treatments often use KEYTRUDA® (pembrolizumab). Sometimes they add chemotherapy. These can help, but often cause significant side effects (toxicity). Benefits, like keeping cancer in check, can be modest. This is especially true for patients who don't respond well to initial therapies. If KEYTRUDA® doesn't work, options are scarcer. Some older chemotherapy offers very low response rates and short survival.
• New Needs from Evolving Treatments: HNSCC treatment constantly changes. New therapies emerge, and existing ones are used earlier. This creates new patient groups. They have tried many treatments and have few effective options left. Pyxis believes MICVO's unique targeting could fill these gaps. This is especially true for patients who have failed other therapies.

Pyxis's strategy is clear. They want to lead in ADCs. They aim to develop MICVO to meet this unmet need. They also form alliances to fund research and development. They also want to maximize their intellectual property and technology platforms. These include Flexible Antibody Conjugation Technology (FACT) and the APXiMAB™ platform. They acquired APXiMAB™ from Apexigen, Inc. These are key for developing new ADCs.

Their Money Situation and Big Moves

Pyxis Oncology is in the development phase. They often need to raise money for research and operations. They were active in raising money during the fiscal year ending December 31, 2025:

• Raising Money: They raised funds by issuing common stock. They also issued "pre-funded warrants." These are like options to buy stock later at a set price. They also use an "At-The-Market Offering Program." This lets them sell shares into the stock market as needed. This is common for biotech companies. It keeps their research and development funded. However, the company stated a serious concern. There's "substantial doubt about their ability to continue as a going concern." This means they expect to run out of money within 12 months. This is based on their current plan and cash. They need to raise much more money soon to keep operating. For investors, this means high risk. Future stock offerings could significantly reduce your ownership percentage. Asset sales or even bankruptcy are possible if they can't get funding. They explicitly state they "will require substantial additional capital." If they don't get it, they might delay or cut research. They could even stop operations.
• Selling Future Payments: They made a notable move. They sold some future royalty rights. For example, on March 25, 2024, they sold rights for a potential drug to Novartis. This means they get cash now. In return, they give up a portion of future sales if the drug succeeds. It's a way to fund operations immediately.
• Managing Cash: They hold some funds in safe investments. These include money market funds and U.S. Treasury securities. This is a smart way to manage cash.
• Company Size Snapshot: As of June 30, 2025, their publicly traded stock was worth about $64.4 million. This excludes shares held by insiders. As of March 20, 2026, they had about 62.8 million common shares issued.

How They Performed (A Look at the Big Picture)

The company is a clinical-stage company with a limited operating history. This means they are still developing drugs. As expected for this stage, they've "incurred significant losses since they started." They also expect to "continue to incur losses for several years." They "may never achieve or maintain profitability." This is common for biotech companies. Investors must understand that profits aren't expected soon.

However, "performance" for a biotech also means drug trial progress. Here's how MICVO has been doing:

Early Lab and Animal Study Results (Preclinical and Translational Data)

Before human trials, drugs undergo extensive lab and animal testing. These early results show how the drug works. They also check if it's safe and effective enough to proceed. Pyxis Oncology has shared some promising data for MICVO:

• Broad Anti-Tumor Activity (AACR 2025): In April 2025, they presented lab and animal study data (PDX models). MICVO showed strong anti-tumor activity across ten solid tumor types. In fact, 45% of these models showed strong tumor growth inhibition. This means tumors stopped growing or shrank a lot. Some even showed complete responses, where the tumor disappeared. These studies confirmed MICVO's unique drug release method worked as expected in the tumor environment.
• Boosting the Immune System (Preclinical Combination Studies): They tested a mouse version of MICVO. It was combined with an anti-PD-1 therapy (like KEYTRUDA®). This was done in animal models of triple-negative breast cancer. The results were very encouraging:
  • The combination was more effective than either treatment alone. It significantly stopped tumor growth and improved survival.
  • MICVO "heated up" tumors. It boosted the immune response, attracting more immune cells to fight cancer.
  • In one model, the combination led to complete responses in 9 of 15 animals.
  • It even created lasting "immunological memory." This means the body better fought future cancer recurrence.
  • Importantly, this synergistic effect appeared even when anti-PD-1 therapy alone failed. This suggests MICVO could help patients who don't respond to current immune therapies.
• How MICVO Works (ESMO & AACR-NCI-EORTC 2025): In October 2025, more data reinforced MICVO's unique mechanism. These studies showed MICVO binds strongly and specifically to EDB+FN in the tumor. This lets it stay anchored and release its drug effectively. They also confirmed the drug releases outside the cell in the tumor's acidic environment. MICVO can remodel the tumor's environment and activate the immune system.

These early findings strongly support Pyxis Oncology's focus on MICVO. This applies to MICVO alone and combined with immune therapies like KEYTRUDA®.

Clinical Trial Results

Here's how MICVO has been doing in human trials:

• MICVO as a Standalone Treatment (Monotherapy):
  • Early Phase 1 Results (November 2024 report, data up to October 2024): An early study included 80 patients across nine tumor types. MICVO showed the strongest positive response in R/M HNSCC. Six R/M HNSCC patients could be evaluated. 50% saw their tumors shrink significantly (Objective Response Rate, or ORR). This included one complete disappearance and two significant shrinkages. All six patients (100%) had their disease controlled. This means it didn't grow or it shrank. Doses ranged from 3.6 mg/kg to 5.4 mg/kg. Based on results, they chose 5.4 mg/kg for further study.
  • Updated Phase 1 Results (December 2025 report, data up to November 2025): A larger group had 18 R/M HNSCC patients. 13 could be evaluated for effectiveness. The confirmed ORR was 46% (6 of 13 patients). This included one complete cancer disappearance. The disease control rate was very high at 92% (12 of 13 patients). These positive responses appeared even in heavily pre-treated patients. This included those who had prior platinum-based chemotherapy and checkpoint inhibitors.
  • Safety (Monotherapy): MICVO was generally well tolerated. They saw no severe (Grade 4) drug-related side effects from the payload. There were also no deaths (Grade 5 events). However, patients with higher body weight had more severe side effects. (Grade ≥3 in 56% of patients). They were also more likely to stop treatment (28% of patients). The company is adjusting dosing for heavier patients. They might cap the maximum dose or use a different weight calculation. They are also using AIBW (Adjusted Ideal Body Weight) dosing in ongoing studies. This new approach has improved tolerability in similar drugs without losing effectiveness. This is a positive step. It improves safety while keeping the drug effective.
• MICVO in Combination with KEYTRUDA® (Pembrolizumab):
  • Partnership and Study Start (November 2024 & January 2025): Pyxis Oncology partnered with Merck. Merck makes KEYTRUDA®. They will study MICVO alongside KEYTRUDA®. They started a Phase 1/2 study in January 2025. It covers various solid tumors, including HNSCC.
  • Preliminary Combination Results (December 2025 report, data up to November 2025): A small group of seven R/M HNSCC patients received MICVO and KEYTRUDA®. Results were very encouraging. 71% of patients (5 of 7) saw tumors shrink significantly. 100% had their disease controlled. Importantly, these responses appeared even in patients whose cancer grew while on checkpoint inhibitor treatments.
  • Safety (Combination Therapy): This combination was also generally well tolerated. No severe (Grade 3 or 4) drug-related side effects from the MICVO payload occurred. There were also no deaths. No patients stopped treatment due to side effects. They saw no new or unexpected side effects from combining the drugs.

Overall, these early clinical results are positive. They support Pyxis's decision to keep developing MICVO, both alone and with KEYTRUDA®.

What's Next for Pyxis Oncology? (Future Outlook)

The company is moving forward with MICVO:

• Monotherapy Expansion: They finished enrolling about 40 patients. This was for the next phase of their R/M HNSCC monotherapy study in early 2026. They expect to share updated clinical data from this group in mid-2026. This will show how their new weight-based dosing affects safety and effectiveness.
• Big Step Towards Approval: In Q4 2025, they received key feedback and agreement from the U.S. Food and Drug Administration (FDA). This was for a planned pivotal monotherapy study design in R/M HNSCC. A "pivotal study" is a large, critical trial. It's often needed to apply for market approval. This is a significant milestone!
• Combination Therapy Progress: They continue testing MICVO with KEYTRUDA®. They aim to find the "Recommended Phase 2 Dose" (RP2D) for their combination study. They are enrolling patients now. Doses range from 3.6 mg/kg to 5.4 mg/kg of MICVO. This is combined with a fixed dose of KEYTRUDA®. They expect to report updated data from this combination study. This will be for R/M HNSCC patients in the second half of 2026.

Who Else is in the Race? (The Competitive Landscape)

Treating R/M HNSCC is competitive. Several other companies also develop new therapies. Pyxis Oncology isn't alone in solving this problem. Some of the key players and their approaches include:

• Next-Generation EGFR Drugs: Companies like Genmab, Bicara Therapeutics, and Johnson & Johnson (JNJ) develop new antibodies. These target EGFR, another protein often found in cancer cells. Many received "breakthrough designation" from the FDA. This speeds up their review. These companies have ongoing clinical trials. Some are in late stages (Phase 3). They cover standalone and combination therapies in HNSCC.
• Other ADCs: Corbus Pharmaceuticals also develops an ADC, CRB-701. It targets Nectin-4, a different protein, for 2L+ R/M HNSCC.
• Other Treatments: Companies like Nanobiotix explore different treatments. These include radioenhancers, which might be used earlier.

This evolving landscape shows a big unmet need. But many companies try to address it. The market might segment. Different drugs could work best for specific patient groups. This might depend on HPV status or previous treatments. Pyxis Oncology must show MICVO is effective and tolerable. This is especially true for patients who have had many treatments and may be weaker.

What Could Go Wrong? (Risks to Consider)

Investing in Pyxis Oncology has notable risks. The company itself highlights them:

• Reliance on One Drug: Much of their future success depends on MICVO, their main drug candidate. If MICVO fails in trials, isn't approved, or doesn't sell well, it would significantly hurt the company. This risk concentration means any MICVO failure or delay would be catastrophic. This includes development, approval, or sales. It would impact the company's value and ability to survive. They have no other revenue-generating products now.
• Drug Development is Tough: Creating new drugs is long, expensive, and uncertain. Their drug candidates could fail in development. They might face unexpected delays. Unforeseen side effects could stop them from reaching the market. Most drug candidates fail in clinical trials. This is especially true in oncology. A drug's chance of moving from Phase 1 to market approval is usually under 10%. For oncology drugs, it's even lower. This high risk means Pyxis Oncology's R&D investments might not produce marketable products.
• Regulatory Hurdles: Getting FDA approval is lengthy, unpredictable, and time-consuming. There's no guarantee of approval. This would be a major setback. Even with successful trials, regulators like the FDA have strict rules. Approval delays, requests for more studies, or outright rejection could prevent market entry. This would lead to big financial losses and hurt investor confidence.
• Lots of Competition: The oncology (cancer treatment) space is crowded. Many other biotech and pharmaceutical companies compete. Pyxis Oncology must compete effectively to succeed. This intense competition means MICVO needs to stand out. It must show better effectiveness, safety, or convenience. This is true even if approved, to gain market share against other therapies. If MICVO doesn't stand out, sales could be limited. Revenues might be lower than expected, despite successful development.
• Need for Top Talent: They need skilled scientists and managers. This keeps their research and development going. Losing key people could hurt their progress. Losing key staff could disrupt research. It could delay trials or impair strategic decisions. This directly impacts their ability to develop drugs and hit milestones.
• Dependence on Others: They rely on other companies to make their drug candidates for clinical trials. If these manufacturers have problems, trials and approvals could face delays. Relying on contract manufacturers (CMOs) brings risks. These include quality control, manufacturing capacity, supply chain issues, and regulatory compliance. Partner issues could cause manufacturing delays or higher costs. Product recalls are also possible. This jeopardizes trials and future commercial supply.
• Intellectual Property Challenges: They might not get or protect patents and other intellectual property for their drugs. Or they might lose rights by not following agreements (like with Pfizer). If so, other companies could copy their ideas. This makes competition hard. Strong intellectual property protection, mainly patents, is critical. It helps biotech companies secure market exclusivity. It also helps them recover R&D investments. Failing to get or keep strong patent protection is a risk. Competitor challenges to patent validity or infringement are also risks. These could allow generic or biosimilar competition. This would severely reduce potential revenues and market value. Breaking licensing agreements could mean losing rights to key technologies or drug candidates.
• Data Security and Privacy: They handle sensitive patient and company data. This requires great care. Data protection failures or computer system issues could lead to big costs. Legal problems and reputational damage are also risks. Such incidents could disrupt operations. They could also divert resources from core drug development.